SCHEMBL24556935

SCHEMBL24556935

CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4c4ccc(S(=O)(=O)O)cc4)c3n2)COC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.69
IRAK4 Q9NWZ3 2/20 0.69
GAK O14976 1/20 0.69
RIPK2 O43353 1/20 0.69
ULK1 O75385 1/20 0.69
STK10 O94804 1/20 0.69
PRKD3 O94806 1/20 0.69
MAP4K4 O95819 1/20 0.69
LATS1 O95835 1/20 0.69
PAK4 O96013 1/20 0.69
NTRK1 P04629 1/20 0.69
LCK P06239 1/20 0.69
CDK1 P06493 1/20 0.69
APRT P07741 1/20 0.69
RET P07949 1/20 0.69
PDGFRB P09619 1/20 0.69
PHKG2 P15735 1/20 0.69
NQO2 P16083 1/20 0.69
PDGFRA P16234 1/20 0.69
FECH P22830 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25862336 0.94 FLT3 (0.68) FLT3IRAK4GAKRIPK2ULK1
SCHEMBL3189249 0.86 FLT3 (0.78) FLT3IRAK4GAKRIPK2ULK1
Crenolanib SCHEMBL4681285 0.86 FLT3 (0.85) FLT3IRAK4GAKRIPK2ULK1
Crenolanib SCHEMBL29361948 0.86 FLT3 (0.85) FLT3IRAK4GAKRIPK2ULK1
Crenolanib SCHEMBL29352554 0.86 FLT3 (0.85) FLT3IRAK4GAKRIPK2ULK1
SCHEMBL24139877 0.85 FLT3 (0.72) FLT3IRAK4GAKRIPK2ULK1
Crenolanib SCHEMBL29350134 0.82 FLT3 (1.00) FLT3IRAK4GAKRIPK2ULK1
Crenolanib SCHEMBL2730601 0.82 FLT3 (1.00) FLT3IRAK4GAKRIPK2ULK1
Crenolanib SCHEMBL30002138 0.82 FLT3 (1.00) FLT3IRAK4GAKRIPK2ULK1
Crenolanib SCHEMBL29352568 0.82 FLT3 (1.00) FLT3IRAK4GAKRIPK2ULK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202792-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES UNIVERSITY OF HOUSTON SYSTEM (US) 2022-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202792-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES FABP2, MUC1, FABP6 FLT3 1969/4885IRAK4 497/4885GAK 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.